There are 2949 resources available
1150P - Long-term outcomes of stage IIB-IV melanoma patients: Nationwide data from Norway
Presenter: Anna Winge-Main
Session: E-Poster Display
Resources:
Abstract
1151P - Trends in melanoma mortality in Brazil: A 20-year registry-based study
Presenter: Guilherme Nader Marta
Session: E-Poster Display
Resources:
Abstract
1152P - Influence of dietary and physical exercise habits on the melanoma risk: A case-control study
Presenter: Neus Calbet-llopart
Session: E-Poster Display
Resources:
Abstract
1153TiP - A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel cell carcinoma progressing on anti-PD-(L)1 antibody therapy: The MERKLIN 2 study
Presenter: Alexander van Akkooi
Session: E-Poster Display
Resources:
Abstract
1154TiP - A randomized, prospective, multicenter study to assess the impact of early detection of asymptomatic brain metastases (mets) vs standard follow-up on symptomatic brain mets free survival (SBMFS) in pts with previously untreated, unresectable or metastatic melanoma (MM)
Presenter: Eva Munoz Couselo
Session: E-Poster Display
Resources:
Abstract
1155TiP - Pan-tumour study CheckMate 8TT for long-term follow-up of cancer survivors who have participated in trials investigating nivolumab
Presenter: Crystal Denlinger
Session: E-Poster Display
Resources:
Abstract
1163P - Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): An international double-blind, placebo-controlled randomized phase II trial
Presenter: Come Lepage
Session: E-Poster Display
Resources:
Abstract
1164P - Prognostic value of miRNA profiling in neuroendocrine neoplasias (NENs) from lung and gastroenteropancreatic (GEP) origin
Presenter: Paula Espinosa-Olarte
Session: E-Poster Display
Resources:
Abstract
1165P - Subgroup analysis by Ki-67 and primary tumour origins of the randomized, placebo-controlled phase III study of surufatinib in advanced well-differentiated extrapancreatic neuroendocrine tumours (SANET-ep)
Presenter: Zhiwei Zhou
Session: E-Poster Display
Resources:
Abstract
1167P - SILVELUL SCORE: An original or modified immunohistochemical score (IPS or mIPS) in patients (pts) with pancreatic neuroendocrine tumours (PanNET) treated with everolimus or CAPTEM
Presenter: Antonio Viudez
Session: E-Poster Display
Resources:
Abstract